Weedstock Insight (by Sheeba):

The shift towards psychedelic research and therapy signals a more mature and specialized phase for alternative medicine investment. Companies with strong R&D, patent portfolios, and clinical pipelines will differentiate themselves, offering higher-growth potential than traditional cannabis or wellness plays. This sector aligns with the long-term trend of alternative compounds integration into mainstream medicine and consumer health products.

Sources: